Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncotarget. 2016 Feb 23;7(8):9340-52. doi: 10.18632/oncotarget.7009.

Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo.

Jiang Z1,2,3, Zhang H1,2, Wang Y1,2, Yu B1,2, Wang C1,2, Liu C1,2, Lu J4, Chen F1,2, Wang M1,2, Yu X1,2, Lin J5, Pan X6, Wang P7, Zhu H1,2.

Author information

1
Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.
2
Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China.
3
Department of Anesthesiology, Second Military Medical University, Shanghai, P.R. China.
4
Training Department, Second Military Medical University, Shanghai, P.R. China.
5
School of Clinic Medicine, Second Military Medical University, Shanghai, P.R. China.
6
Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
7
National Key Laboratory of Medical Immunology and Institute of Immunology, Second Military Medical University, Shanghai, P.R. China.

Abstract

Cancer immunotherapy is the use of the immune system to treat cancer. Our current research proposed an optional strategy of activating immune system involving in cancer immunotherapy. When being treated with 2% DMSO in culture medium, Hepa1-6 cells showed depressed proliferation with no significant apoptosis or decreased viability. D-hep cells, Hepa1-6 cells treated with DMSO for 7 days, could restore to the higher proliferation rate in DMSO-free medium, but alteration of gene expression profile was irreversible. Interestingly, tumors from D-hep cells, not Hepa1-6 cells, regressed in wild-type C57BL/6 mice whereas D-hep cells exhibited similar tumorigenesis as Hep1-6 cells in immunodeficient mice. As expected, additional Hepa1-6 cells failed to form tumors in the D-hep-C57 mice in which D-hep cells were eliminated. Further research confirmed that D-hep-C57 mice established anti-tumor immunity against Hepa1-6 cells. Our research proposed viable tumor cells with altered biological features by DMSO-treatment could induce anti-tumor immunity in vivo.

KEYWORDS:

DMSO; anti-tumor immunity; cancer immunotherapy

PMID:
26824185
PMCID:
PMC4891044
DOI:
10.18632/oncotarget.7009
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Support Center